Life Sciences

The JIMCO Life Sciences Fund is building a diversified investment portfolio to advance the Jameel Family’s ambition of accelerating access to modern medical care for those who need it most, and so actively driving toward a more inclusive approach to healthcare for all.

To accomplish this, we’re partnering with leading venture capital investors to deploy capital through fund commitments and directly into selected opportunities.

In this way, the JIMCO Life Sciences Fund is focused on supporting real-world, tangible solutions that respond to the rising global demand for modern medical care.

The rapid innovation cycle in global health technology guides our investment focus areas, where we have prioritized digital health and AI, precision medicine, advanced medical devices and techniques, diagnostics, genomics, regenerative medicine, and animal health.

Emerging technologies and innovative business models in these areas present significant opportunities for sustainable growth and meaningful societal benefit for underserved populations, particularly in the ‘Global South’.

This is quickly impacting the developing regulatory environment, in turn accelerating drug and device filing, registration and market authorization as well as licensing arrangements.

We seek to both invest in emerging ideas and connect businesses to new growth opportunities particularly in rapidly developing and high demand markets.

Continuing the Jameel Family’s philanthropic word that co-founded the Jameel Clinic at MIT and the Jameel Institute at Imperial College London, the JIMCO Life Sciences Fund is extending this commitment to the future of health, championing innovation that increases inclusivity for all.